Press releaseGlobe Newswire
Clearmind Medicine
CMND · NASDAQ
$5.87−$0.13 (−2.17%)TodayMarket closed ·
Prev close $6.00
Latest news
- News
Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide
- Press releaseGlobe Newswire
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
- Press releaseGlobe Newswire
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsHenry Khederian
Clearmind Medicine Stock Slides Friday: What's Happening?
- News
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
- Press releaseGlobe Newswire
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
- Press releaseGlobe Newswire
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
- NewsVandana Singh
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
- News
Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment
- Press releaseGlobe Newswire
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
- News
Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress Disorder
- NewsAvi Kapoor
Gold Falls 1%; Amer Sports Earnings Top Views
- NewsAvi Kapoor
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Dow Gains Over 200 Points; US Retail Sales Top Estimates
- NewsAvi Kapoor
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
- NewsDylan Berman
Why Is Clearmind Stock Rising Monday?
- News
Market-Moving News for April 20th
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views
- NewsAvi Kapoor
Nasdaq Surges 200 Points; Citigroup Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
- NewsAvi Kapoor
Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsEvette Mitkov
Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On?
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAlex Perry
Why Is Clearmind Stock Down Today?
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
- NewsAdam Eckert
SciSparc Shares Are Soaring Monday: What's Going On?
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.